Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rami Kotb

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Oncogene|March 1, 2005
Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitroValérie Soenen-Cornu, Cristina Tourino, Marie-Laure Bonnet, et al.
Blood Cancer Journal|September 11, 2024
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trialArleigh McCurdy, Donna Reece, Martha L Louzada, et al.
Nature Medicine|January 4, 2024
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trialSuzanne Trudel, Arleigh McCurdy, Martha L Louzada, et al.
Haematologica|October 9, 2025
Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial reviewHarshal Senthil, Scott Streilein, Theresa Whiteside, et al.
British Journal of Haematology|February 9, 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group databaseVictor H Jimenez-Zepeda, Christopher Venner, Arleigh McCurdy, et al.
Blood|October 24, 2002
Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safetyFrance Noizat-Pirenne, Ketty Lee, Pierre-Yves Le Pennec, et al.
Cancer Medicine|September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group DatabaseHira Mian, Richard LeBlanc, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group DatabaseHira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Oncogene|March 1, 2005
Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitroValérie Soenen-Cornu, Cristina Tourino, Marie-Laure Bonnet, et al.
Blood Cancer Journal|September 11, 2024
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trialArleigh McCurdy, Donna Reece, Martha L Louzada, et al.
Nature Medicine|January 4, 2024
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trialSuzanne Trudel, Arleigh McCurdy, Martha L Louzada, et al.
Haematologica|October 9, 2025
Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial reviewHarshal Senthil, Scott Streilein, Theresa Whiteside, et al.
British Journal of Haematology|February 9, 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group databaseVictor H Jimenez-Zepeda, Christopher Venner, Arleigh McCurdy, et al.
Blood|October 24, 2002
Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safetyFrance Noizat-Pirenne, Ketty Lee, Pierre-Yves Le Pennec, et al.
Cancer Medicine|September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group DatabaseHira Mian, Richard LeBlanc, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group DatabaseHira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
Pageof 7